What the future holds for social media data analysis

The dramatic rise in the use of Social Media (SM) platforms such as Facebook and Twitter provide access to an unprecedented amount of user data. Users may post reviews on products and services they bought, write about their interests, share ideas or give their opinions and views on political issues. There is a growing interest in the analysis of SM data from organisations for detecting new trends, obtaining user opinions on their products and services or finding out about their online reputations. A recent research trend in SM analysis is making predictions based on sentiment analysis of SM. Often indicators of historic SM data are represented as time series and correlated with a variety of real world phenomena like the outcome of elections, the development of financial indicators, box office revenue and disease outbreaks. This paper examines the current state of research in the area of SM mining and predictive analysis and gives an overview of the analysis methods using opinion mining and machine learning techniques

Magnesium 2000 postmarket evaluation : Guideline adherence and intraprocedural performance of a sirolimus-eluting resorbable magnesium scaffold

Background The Magmaris bioresorbable magnesium scaffold was successfully tested in in-vitro and in clinical premarket studies. Subsequently the Magmaris postmarket program aimed to review intraprocedural data of at least 2000 patients to assess user preferences, guideline adherence and intraprocedural performance in clinical routine. Methods This international multicentre survey encompasses data from 356 hospitals across 45 countries. As part of the certification for Magmaris implantation, each hospital had to complete consecutive post-market evaluation forms of their first 10 commercial Magmaris patients. Results From June 2016 to May 2018, data on 2018 implantations were collected. Main reasons for selecting Magmaris was patients' life expectancy (67%, n = 1359) and low or not calcified lesions, (67%, n = 1357). Magmaris was successfully deployed in 99% of cases (n = 1995), predilatation was performed in 95% (n = 1922) and post-dilatation in 87% (n = 1756). Physicians rated the overall performance and the pushability as good or very good in 96% of cases (n = 1799). Guide wire friction, trackability, and conformability were rated as good or very good in 94% of cases, and crossability in 93%. The majority of patients were scheduled to receive dual antiplatelet therapy for up to 12 months. Conclusion Generally, implantation guidelines were adhered to and theoretical advantages of the metal scaffold observed in in-vitro tests have translated into practice with good intraprocedural performance outcomes, confirming the controlled roll-out of this novel technology into clinical practice. (C) 2019 The Authors. Published by Elsevier Inc.Peer reviewe

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Data mining in IoT: data analysis for a new paradigm on the Internet

This paper provides an overview on Data Mining (DM) technologies for the Internet of Things (IoT). IoT has become an active area of research, since IoT promises among other to improve quality of live and safety in Smart Cities, to make resource supply and waste management more efficient, and optimize traffic. DM is highly domain specific and depends on what is being mined for. For instance, if IoT is used to optimize traffic in a Smart City to reduce traffic jams and to find parking spaces quicker, different types of data needs to be collected and analysed from an eHealth solution, where IoT is used in a Smart Home to monitor the well being of patients or elderly people. IoT connects things that can collect numeric data from smart sensors, streaming data from cameras or route information on maps. Depending on the type of data, different techniques need to be adopted to analyse them. Also, many IoT applications analyse data from different devices and correlate them to make predictions about possible machine failures in production sites or looming emergency situations in Smart Buildings in a home security application. DM techniques need to handle the heterogeneity of IoT data, the large volumes of data and the speed at which they are produced. This paper explores the state of the art DM techniques for IoT

LINESHAPE STUDY OF THE J=3−2J=3-2 ROTATIONAL TRANSITION OF CO PERTURBED BY N2N_{2} AND O2O_{2}

Author Institution: Laboratoire de Physique des Lasers, Atomes et Mol\'{e}cules; Laboratoire de Photophysique Mol\'{e}culaire, Universit\'{e} de Paris-SudWe report on the collisional relaxation of the $J=3-2$ rotational line of CO induced by nitrogen and oxygen. Measurements have been made by using a millimeter wave video-type spectrometer at several temperatures between 240 and 400K. In the 20-400 m Torr pressure range investigated, significant deviations from the Voigt profile have been observed. The observed lineshapes have been studied by means of a quasi-analytical speed dependent Galatry profile. This allows to point out a correlation between the parameters describing the speed dependence of relaxation and the molecular diffusion. The retrieved collisional relaxation coefficients and their temperature dependence both favourably compare to previous reported measurements. Theoretical results obtained from the Robert-Bonamy collisional formalism and from the brownian motion theory allows to consider the possible origins of observed lineshapes

VIBRATION-ROTATIONAL INTERACTIONS IN THE STATES ν2=1\nu_{2} = 1 and ν5=1\nu_{5}=1 OF 13CH3F^{13}CH_{3}F.

Author Institution: Laboratoire de Spectroscopic Hertzienne., Universite de Lille I. F.; J. Heyrovsky Institute of Physical Chemistry and Electrochemistry., Czech Academy of Sciences.; Physikalisch Chemisches Institut., Justus-Liebig Universitat.; Institute of Applied Physics., Russian Academy of Sciences.; Huygens Laboratory., Leiden UniversityThe submillimeterwave spectra were measured of the rotational transitions in the $\nu_{2}=1$ and $\nu_{5}=1$ states of $^{13}CH_{3}F$. Almost 3000 lines were assigned in the high resolution infrared spectra of the $\nu_{2}$ and $\nu_{5}$ bands including 142 lines of the $Ak = \pm 2$ forbidden transitions. A variational approach was applied to the analysis of the $\nu_{2}$ and $\nu_{5}$ bands which are strongly perturbed by the $x-y$ Coriolis and $``2. 1''$ I-type interactions ($E_{2} = 1453.658 cm^{-1}$ and $E_{5} = 1465.576 cm^{-1}$). Combination differences were generated from these wavenumbers to determine very precise ground state parameters of $^{13}CH_{3}F$. The results of a computer search for the coincidences between the energy levels of the ortho-and para-states of $12CH_{3}F$ and $^{13}CH_{3}F$ were used in a new theoretical interpretation of the ortho-para conversion rates in both molecules